Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.

19 May, 2021 | 08:47h | UTC

International COVID-19 trial to restart with focus on immune responses – Nature

 

COVID vaccines can block variant hitting Asia, lab study finds – “Assays using live SARS-CoV-2 offer hope that the vaccines made by Pfizer and Moderna will protect against a viral strain first seen in India”.

18 May, 2021 | 07:56h | UTC

COVID vaccines can block variant hitting Asia, lab study finds – Nature

See also: Pfizer, Moderna vaccines effective against Indian variants: study – MedicalXpress

 

Commentary on Twitter

 

Systematic review: Treatment of gastro-esophageal reflux disease to help manage asthma in adults and children may result in reduced use of rescue medications, but the benefits on the number of exacerbations and hospital utilization remain uncertain.

18 May, 2021 | 07:27h | UTC

Pharmacological and surgical interventions for the treatment of gastro‐oesophageal reflux in adults and children with asthma – Cochrane Library

Summary: Treatment of gastro-oesophageal reflux disease to help manage asthma in adults and children – Cochrane Library

 

[Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age.

17 May, 2021 | 08:53h | UTC

BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant – The Lancet

News release: Delaying second Pfizer vaccines to 12 weeks significantly increases antibody responses in older people, finds study – University of Birmingham

Commentaries: Delaying a COVID vaccine’s second dose boosts immune response – Nature AND Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds – Health Policy Watch AND Delay in giving second jabs of Pfizer vaccine improves immunity – The Guardian AND Expert reaction to preprint looking at the immune response in older people after vaccination the Pfizer-BioNTech COVID-19 vaccine with either a 3-week or a 12-week dosing schedule – Science Media Centre

 

‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo.

17 May, 2021 | 08:45h | UTC

‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo – STAT

Related: COVID-19 Vaccines in Patients With Cancer—A Welcome Addition, but There Is Need for Optimization – JAMA Oncology

 

Perspective | New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications.

14 May, 2021 | 08:43h | UTC

New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications – New England Journal of Medicine

 

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

14 May, 2021 | 08:46h | UTC

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data – The Lancet

Commentaries: More side effects noted after using 2 different COVID vaccines – CIDRAP AND Covid vaccines: Mixing increases reports of mild side-effects – BBC

 

Perspective | Vaccines seem to work well against coronavirus variants. It’s also complicated.

14 May, 2021 | 08:41h | UTC

Vaccines seem to work well against coronavirus variants. It’s also complicated – STAT

 

Review: How to interpret and use COVID-19 serology and immunology tests.

14 May, 2021 | 08:36h | UTC

How to interpret and use COVID-19 serology and immunology tests – Clinical Microbiology and Infection

 

Systematic review: Combination fixed‐dose beta-agonist and steroid inhaler as required is clinically effective in adults and adolescents with mild asthma.

14 May, 2021 | 08:23h | UTC

Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library

Summary: Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library

 

RCT: Tezepelumab can reduce exacerbations in adults and adolescents with severe, uncontrolled asthma.

14 May, 2021 | 08:25h | UTC

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma – New England Journal of Medicine

Commentary: New drug shows promise against tough-to-manage asthma – MedicalXpress

 

Practice Guideline: Prevention and management of allergic reactions to food in child care centers and schools

11 May, 2021 | 09:06h | UTC

Prevention and management of allergic reactions to food in child care centers and schools: Practice guideline – Journal of Allergy and Clinical Immunology

 

Commentary on Twitter (thread – click for more)

 

Covid-19: Most people admitted to hospital after vaccination were infected before immunity could develop, research shows.

10 May, 2021 | 01:14h | UTC

Covid-19: Most people admitted to hospital after vaccination were infected before immunity could develop, research shows – The BMJ

 

Commentary on Twitter

 

Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

7 May, 2021 | 08:33h | UTC

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study – The BMJ

Editorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ

Commentaries: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion AND Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion AND Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre

 

Commentary on Twitter

 

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

7 May, 2021 | 08:30h | UTC

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity – The Lancet Respiratory Medicine

 

Commentary on Twitter

 

Cohort study shows inadequate antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients.

6 May, 2021 | 09:01h | UTC

Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients – Prospective cohort study – Clinical Microbiology and Infection

 

Commentary on Twitter

https://twitter.com/hildabast/status/1390097665451462656

 

Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high, at 97.4%.

6 May, 2021 | 09:06h | UTC

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants – New England Journal of Medicine

Commentary: Pfizer-BioNTech vaccine offers strong protection against key variants of concern, real-world data from Qatar shows – The Washington Post

 

Commentary on Twitter

https://twitter.com/DrEricDing/status/1390107362485211136

 

Organ transplant recipients remain vulnerable to Covid-19 even after second vaccine dose.

6 May, 2021 | 09:03h | UTC

Organ Transplant Recipients Remain Vulnerable to Covid-19 Even After Second Vaccine Dose – Johns Hopkins Medicine

Original Study: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients – JAMA

 

[Preprint] SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity

5 May, 2021 | 08:40h | UTC

SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity – medRxiv

Commentary: SARS-CoV-2 antibodies are detectable up to a year after infection, finds study – News Medical

 

Commentary on Twitter

https://twitter.com/hildabast/status/1388963453134532609

 

Prior SARS-CoV-2 infection boosts response to variants after first vaccine dose

4 May, 2021 | 08:51h | UTC

Prior SARS-CoV-2 infection boosts response to variants after first vaccine dose – Imperial College London

Original study: Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose – Science

 

Commentary on Twitter (thread – click for more)

 

Study: Most patients who develop a non-IgE-mediated hypersensitivity reaction to nafcillin can be safely treated with cefazolin

4 May, 2021 | 08:36h | UTC

Tolerability of Cefazolin in Nafcillin-Intolerant Patients for the Treatment of Methicillin-Susceptible Staphylococcus aureus Infections – Clinical Infectious Diseases

Related: Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin – Antimicrobial Agents & Chemotherapy

 

Commentary on Twitter

 

Case series of 12 patients with cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination – all women younger than 60 years, with symptoms from 6 to 15 days after vaccination

3 May, 2021 | 05:43h | UTC

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 – JAMA

Editorial: Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine – JAMA

See also: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021 – Centers for Disease Control and Prevention AND Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 – Centers for Disease Control and Prevention

Related: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

 

Review: Systemic and organ-specific immune-related manifestations of COVID-19 – over 70 different systemic and organ-specific immune-related disorders have been reported

28 Apr, 2021 | 08:42h | UTC

Systemic and organ-specific immune-related manifestations of COVID-19 – Nature Reviews Rheumatology

 

Long Covid: Largest post-acute COVID-19 study to date examined the health outcomes in more than 73,000 people who’d had COVID-19 and were not hospitalized

23 Apr, 2021 | 08:48h | UTC

High-dimensional characterization of post-acute sequalae of COVID-19 – Nature

Commentary: Among COVID-19 survivors, an increased risk of death, serious illness – Washington University School of Medicine

 

Commentary on Twitter (thread – click for more)

 

RCT: Single-Dose Johnson & Johnson Vaccine has 85% efficacy against severe/critical Covid-19 and maintains efficacy against variant B.1.351

22 Apr, 2021 | 08:50h | UTC

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 – New England Journal of Medicine

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.